INCY FDA decision — May 1, 2026
✓ APPROVED
Incyte Corporation — Jakafi XR (ruxolitinib) · Myelofibrosis, acute acute graft-versus-host disea.
Run-up into the decision (T-120 → T+5) PDUFA 5/1/26 $110.57 $90.3 11/14/25 Daily close, T-120 (11/14/25) through T+5. Run-up high $110.57 on 1/12/26, low $90.3 on 3/30/26 (T-120 to T-1). FDA decision 5/1/26. Historical price action, not a forecast.
Key facts
FDA decision date 2026-05-01
Outcome Approved
Drug / candidate Jakafi XR (ruxolitinib)
Company Incyte Corporation
120-day run-up (T-120→T-1) -9.4%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio